Shire model to defend Adderall exclusivity

Share this article:
Shire has written to the FDA demanding that makers of drugs rivaling its attention deficit hyperactivity disorder (ADHD) treatment for children, Adderall, conduct lengthy clinical trials to prove their drugs have the same effect.
According to published reports, analysts are uncertain the FDA will order the trials, but they suspect that its deliberations could delay approval for rival drugs beyond fall 2006, when generic versions of Adderall are expected on the market.
Shire said in a petition to the FDA that rival Barr Laboratories and others should have to prove their drug versions are metabolized by children in exactly the same way and over the same number of hours.
A similar petition by Johnson & Johnson on its ADHD drug Concerta has delayed approval of generic versions for more than a year.
Other efforts to extend exclusivity of Adderall include suing Barr for patent infringement in a U.S. case that is set to begin in January.
Share this article:

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.